Patents by Inventor Koichiro Kumai

Koichiro Kumai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODY, GENE ENCODING THE ANTIBODY, HYBRIDOMA, PHARMACEUTICAL COMPOSITION, AND DIAGNOSTIC REAGENT
    Publication number: 20090053300
    Abstract: Disclosed is a monoclonal antibody which has a heavy chain variable region containing amino acid sequences depicted in SEQ ID NOs:74, 76 and 78 and a light chain variable region containing amino acid sequences depicted in SEQ ID NOs:80, 82 and 84. The monoclonal antibody can be used as a cancer therapeutic agent which acts selectively on a cancer tissue of non-small lung cancer, pancreatic cancer, gastric cancer or the like.
    Type: Application
    Filed: February 23, 2007
    Publication date: February 26, 2009
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, KEIO UNIVERSITY
    Inventors: Saiko Hosokawa, Yoko Hirakawa, Kazumasa Fukuda, Rieko Nakamura, Yoshiro Saikawa, Masahiko Aoki, Koichiro Kumai
  • Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
    Patent number: 7396915
    Abstract: A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: July 8, 2008
    Assignees: Mitsubishi Pharma Corporation, Keio University
    Inventors: Saiko Hosokawa, Masahiko Aoki, Yoko Hirakawa, Seima Itami, Hiroe Umeki, Yoshiro Saikawa, Koichiro Kumai, Kazumasa Fukuda
  • Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
    Publication number: 20060088538
    Abstract: A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.
    Type: Application
    Filed: February 27, 2004
    Publication date: April 27, 2006
    Applicants: Mitsubishi Pharma Corporation, Keio University
    Inventors: Saiko Hosokawa, Masahiko Aoki, Yoko Hirakawa, Seima Itami, Hiroe Umeki, Yoshiro Saikawa, Koichiro Kumai, Kazumasa Fukuda